407 related articles for article (PubMed ID: 29543644)
1. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry.
Stearns LM; Abd-Elsayed A; Perruchoud C; Spencer R; Hammond K; Stromberg K; Weaver T
Anesth Analg; 2020 Feb; 130(2):289-297. PubMed ID: 31567325
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center.
Dupoiron D; Bienfait F; Carvajal G; Seegers V; Douillard T; Jubier-Hamon S; Delorme T; Julienne A; Pluchon YM; Ribault N; Nader E; Lebrec N
Reg Anesth Pain Med; 2023 Nov; ():. PubMed ID: 37973378
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Initial Intrathecal Drug Ratio for Refractory Cancer-Related Pain for Early Pain Relief. A Retrospective Monocentric Study.
Dupoiron D; Leblanc D; Demelliez-Merceron S; Bore F; Seegers V; Dubois PY; Pechard M; Robard S; Delorme T; Jubier-Hamon S; Carvajal G; Lebrec N
Pain Med; 2019 Oct; 20(10):2033-2042. PubMed ID: 31329956
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study.
Zheng S; He L; Yang X; Li X; Yang Z
Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Intrathecal Drug Delivery: Outcomes, Efficacy, and Risk for Cancer-Related Pain at a High Volume Academic Medical Center.
Sayed D; Monroe F; Orr WN; Phadnis M; Khan TW; Braun E; Manion S; Nicol A
Neuromodulation; 2018 Oct; 21(7):660-663. PubMed ID: 29446171
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Cancer Related Pain: Review of Pathophysiology and Intrathecal Drug Delivery Systems for Pain Management.
Carvajal G
Pain Physician; 2021 Aug; 24(5):E583-E594. PubMed ID: 34323445
[TBL] [Abstract][Full Text] [Related]
8. Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer.
Sindt JE; Odell DW; Dalley AP; Brogan SE
Neuromodulation; 2020 Oct; 23(7):978-983. PubMed ID: 32459393
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.
Lin CP; Lin WY; Lin FS; Lee YS; Jeng CS; Sun WZ
J Formos Med Assoc; 2012 May; 111(5):253-7. PubMed ID: 22656395
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Intrathecal Analgesia With a Wireless Analgesia Pump System in the Home Care of Patients With Advanced Cancer.
Liu HJ; Li WY; Chen HF; Cheng ZQ; Jin Y
Am J Hosp Palliat Care; 2017 Mar; 34(2):148-153. PubMed ID: 26537661
[TBL] [Abstract][Full Text] [Related]
11. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).
Smith TJ; Coyne PJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Cousins M; Pool GE
Ann Oncol; 2005 May; 16(5):825-33. PubMed ID: 15817596
[TBL] [Abstract][Full Text] [Related]
12. Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome.
Herring EZ; Frizon LA; Hogue O; Mejia JU; Rosenquist R; Bolash RB; Machado AG; Nagel SJ
Pain Med; 2019 Mar; 20(3):515-520. PubMed ID: 29889241
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US.
Goel V; Kumar V; Blaes A; Gulati A
Neuromodulation; 2023 Aug; 26(6):1256-1262. PubMed ID: 37318432
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer.
Gilmer-Hill HS; Boggan JE; Smith KA; Frey CF; Wagner FC; Hein LJ
Surg Neurol; 1999 Jan; 51(1):6-11. PubMed ID: 9952116
[TBL] [Abstract][Full Text] [Related]
15. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients.
Smith TJ; Coyne PJ
J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647
[TBL] [Abstract][Full Text] [Related]
16. Spinal analgesia for severe cancer pain: A retrospective analysis of 60 patients.
Kiehelä L; Hamunen K; Heiskanen T
Scand J Pain; 2017 Jul; 16():140-145. PubMed ID: 28850391
[TBL] [Abstract][Full Text] [Related]
17. Long-term intrathecal drug administration for chronic nonmalignant pain.
Duarte RV; Raphael JH; Sparkes E; Southall JL; LeMarchand K; Ashford RL
J Neurosurg Anesthesiol; 2012 Jan; 24(1):63-70. PubMed ID: 21904220
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis.
Duarte R; Copley S; Nevitt S; Maden M; Al-Ali AM; Dupoiron D; Eldabe S
Neuromodulation; 2023 Aug; 26(6):1126-1141. PubMed ID: 35422368
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Smith TJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Coyne PJ; Pool GE;
J Clin Oncol; 2002 Oct; 20(19):4040-9. PubMed ID: 12351602
[TBL] [Abstract][Full Text] [Related]
20. Rationale and Recent Advances in Targeted Drug Delivery for Cancer Pain: Is It Time to Change the Paradigm?
Dupoiron D; Duarte R; Carvajal G; Aubrun F; Eldabe S
Pain Physician; 2022 May; 25(3):E414-E425. PubMed ID: 35652767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
